Home
About
Overview
Our Team
Contact Us
Science
Our Science
MNTF Discovery
GM6 Development
GM6 and the Blood-Brain-Barrier
Neuroprotection
Drug Properties
Pipeline
CNS Indications
GM6 in CNS
ALS
Parkinson's Disease
Alzheimer's Disease
Stroke
Multiple Sclerosis
Spinal Cord Injury
Newsroom
What's New
Media
Contact

Genervon

Home
About
Overview
Our Team
Contact Us
Science
Our Science
MNTF Discovery
GM6 Development
GM6 and the Blood-Brain-Barrier
Neuroprotection
Drug Properties
Pipeline
CNS Indications
GM6 in CNS
ALS
Parkinson's Disease
Alzheimer's Disease
Stroke
Multiple Sclerosis
Spinal Cord Injury
Newsroom
What's New
Media
Contact
Genervon Biopharmaceuticals
May 8, 2017

You are invited to our luncheon presentation - World Preclinical Congress, Translational Strategies In CNS

Genervon Biopharmaceuticals
May 8, 2017
20170508invitation.jpg

Contact
Genervon Biopharmaceuticals LLC
Emily Wang, 323-721-5500
info@genervon.com 
Website: http://www.genervon.com

Newer PostGM604 Is a Multi-Target Regulator That Provides a Novel Treatment Strategy for ALS
Older PostConfidential data from Genervon ALS Phase 2A clinical trial were released and published
Back to Top

Genervon Biopharmaceuticals LLC
1055 E. Colorado Blvd., Suite 500, Pasadena, CA 91106 USA
Phone: 323-721-5500, Fax: 323-721-9131
info@genervon.com

 

© 2023 Genervon Biopharmaceuticals, LLC. All rights reserved. All other trademarks or trade names are the property of their respective holders.